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Abstract 
Background: Evidences have shown that anti-M3 muscarinic acetylcholine receptor IgG (anti-M3 
mAChR IgG) are clinically useful autoantibody that exert a cholinergic pharmacologic effect bind-
ing and interacting with M3 mAChR at the level of exocrine gland (salivary and ocular). Aims: The 
aim of this study was to determine the associations between serum level of anti-M3 mAChR IgG in 
patients with systemic lupus erythematosus (SLE) and other autoantibodies, serum prostaglandin 
E2 (PGE2), and clinical manifestations. Methods: Serum autoantibodies against M3 mAChR synthetic 
peptide were measured by enzyme-linked immuno absorbent assay (ELISA) using, as an antigen, a 
25-mer peptide K-R-T-V-P-D-N-Q-C-F-I-Q-F-L-S-N-P-A-V-T-F-G-T-A-I corresponding to the amino ac-
id sequence of the second extracellular loop of the human M3 mAChR. Serum levels of antinuclear 
antibodies (ANA), anti-Smith (Sm) antibodies, anti-phospholipid (APL) antibodies, and PGE2 were 
determined by ELISA in patients with SLE. Results: We found significantly enhanced titers of an-
ti-M3 mAChR IgG in sera from SLE patients compared with healthy individuals (control). In addi-
tion, serum levels of PGE2 were significantly higher in SLE patients than in control patients and 
were significantly higher in active than in non-active SLE. No correlation was found with other au-
toantibodies present in SLE. By contrast, a positive correlation was found between anti-M3 mAChR 
IgG and PGE2 serum levels in SLE. Conclusions: As anti-M3 mAChR antibodies present in the sera of 
SLE patients may be another factor in the pathogenesis of this disease, and the increment of PGE2 
in the sera of SLE has a modulatory action on the inflammatory process, suggesting that the pres-
ence of these autoantibodies against M3 mAChR may contribute to sustained immune deregulation 
and the strong inflammatory component observed in SLE. 
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1. Introduction 
The onset and development of autoimmune disease (AID) are the consequence of interactions between genetic 
and environmental factors, which result in dysregulation of the immune system, and are characterized by the 
presence of autoantibodies and autoreactive T cells. Under these circumstances, immune system antimicrobial 
defenses react against normal components of the body and result in organ-specific or systemic immunopatholo-
gy. Autoantibodies may also appear in the blood of healthy individuals or in some special situations, such as in-
fection and the pre-clinical phase of infectious diseases [1]-[3]. 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of multiple 
autoantibodies [4]-[8], with an inflammatory/necrotic phenomenon in different tissues [9] [10]. This condition is 
associated with hyperactivity of B cells, and different immuno-regulatory abnormalities [11] [12]. In addition, T 
cells from SLE patients exhibit defects in early activation events as well as an impaired proliferative response to 
mitogenic lectins [12] [13]. Furthermore, anti-nuclear (ANA), anti-Smith (anti-Sm), anti-phospholipid (APL), 
and other autoantibodies are detected in patients with SLE [4] [14] [15]. One early study, in which 23 asympto-
matic pregnant women with positive anti-Ro or anti-La titers were followed for many years, reported that four 
subjects developed SLE, which suggested that anti-Ro or anti-La antibodies preceded the development of SLE 
[16]. In another study, Aho et al. reported that SLE patients were positive for ANA before the onset of SLE and 
the percentage was much higher than that of controls which was a much higher rate than controls [17]. Moreover, 
the results from the United States Department of Defense Serum Repository showed that the presence of ANA, 
anti-Ro, anti-La, anti-double strain deoxyribonucleic acid (anti-ds DNA), anti-Sm, APL, anti-ribonucleo protein 
(anti-nRNP) antibodies and rheumatoid factor (RF) preceded the onset of SLE [18]-[20]. Among SLE patients, 
88% were positive for at least one of these autoantibodies, which was a much higher percentage than healthy 
controls, and the prevalence of these autoantibodies increased after diagnosis [21] [22]. Anti-Ro, anti-La, and 
APL antibodies were the earliest detectable autoantibodies during the pre-clinical phase of rheumatoid arthritis 
(RA) [18]-[22]. In addition, the presence of these autoantibodies was associated with incipient severe SLE. For 
example, patients who were positive for anti-ds DNA antibodies often developed renal disease [22] [23], pa-
tients who were positive for IgG RF were more likely to develop arthritis [18], and positive APL was associated 
with malar rash and photosensitivity [19]. In addition, regular patterns exist among these autoantibodies. The 
majority of La-positive pre-clinical SLE patients were also Ro-positive, and a significant overlap was observed 
between patients positive for anti-ds DNA antibody and those positive for anti-chromatin antibody [20]. 
A recently published nested case-control study showed that 66% of Sjögren Syndrome (SS) patients were 
positive for ANA, RF, and anti-La or anti-Ro antibodies approximately 5 years before the onset of SS. A maxi-
mum of 18 years elapsed between positivity for these antibodies and the onset of SS in these subjects [23]. The 
seropositive rate for these antibodies and the anti-M3 muscarinic acetylcholine receptor (mAChR) autoantibo-
dies increased as the onset of SS neared [24]-[26]. In conclusion, the evidence suggests that these autoantibodies 
are predictors of SS. Moreover, the presence of these autoantibodies in the serum of patients with SLE is another 
topic of discussion in SLE pathogenesis. 
The autoimmune nature of lupus and its predominant inflammatory component was accompanied by the ex-
pression of cyclo-oxygenase-2 (COX-2) in the inflammatory areas, with the subsequent release of arachidonic 
acid via membrane-bound phospholipase A2. The biosynthesis of arachidonic acid by COX-2 led to an en-
hancement of prostanoid production of PGE2 serie, which conduct to the dysregulation in the production of 
proinflammatory cytokines (IL-6, IL-10, and nitric oxide) [27] [28]. Therefore, we focused on the family of 
prostaglandins (PG), which are the result of the oxidative modification of arachidonic acid and its cascade 
products through COX-2 expression and activation in patients with SLE. 
2. Aim 
The aim of our preliminary study was to investigate the inflammatory status in SLE patients compared to active 
and non-active groups by assessing the generation of PGE2 and its association with the presence or absence of 
S. Reina et al. 
 
 3 
anti M3 mAChR autoantibodies and SLE disease activity index (SLEDAI). 
3. Methodology 
3.1. Patients 
Blood samples from 30 patients with SLE, according to the classification criteria of the American College of 
Rheumatology (ACR) [29] were obtained. A total of 26 women subjects and four men subjects with a mean age 
of 41.4 ± 11.9 years were included in the study. Also, blood samples of 30 healthy women subjects with a mean 
age of 39.6 ± 10.2 years were used as controls. Fifteen patients had non-active disease (<3) and 15 were consi-
dered to have active disease (≥3), according to the SLEDAI measured [30] [31]. Most patients were receiving 
low to moderate doses of glucocorticoids as well as immunosuppressive drugs-mainly cyclophosphamide, me-
thotrexate, azathioprine, and chloroquine. No patients with renal failure or conditions different from SLE were 
included in the study. The demographic and clinical characteristics of the study population (SLE patients) and 
normal individuals (controls) are shown in Table 1. All of the patients signed an informed consent form to par-
ticipate in the study, and the investigation was conducted according to the tenets of the Declaration of Helsinki 
of 1975, as revised in 2000. 
3.2. Autoantibody Detection 
ELISAs were performed to measure ANA, anti-Sm, and APL using commercially available ELISA kits (INOVA 
Diagnostic, Inc., San Diego, CA, USA). ELISAs were performed according to the manufacturers’ instructions. 
Values of optical density (OD) at 450 nm were obtained, and the IgG antibody concentrations were calculated 
by extrapolating OD450 values to a standard curve. 
3.3. M3 mAChR Autoantibodies 
The IgG fraction from 30 patients with SLE and 30 normal subjects was independently subjected to affinity 
chromatography on the synthesized peptide covalently linked to AffiGel 15 gel (Bio-Rad, Richmond, CA, USA) 
as described previously [25]. Briefly, the IgG fraction was loaded onto the affinity column equilibrated with 
phosphate-buffered saline (PBS). The non-peptide fraction was first eluted with the same buffer. Specific anti-  
 
Table 1. Demographic and clinical characteristics of SLE patients and healthy individuals.                                     
Clinical characteristics 
 SLE patients Normal individuals 
Number 30 30 
Current age, mean years ± SD 41.4 ± 11.9 39.6 ± 10.2 
Disease duration, mean years ± SD 7.88 ±10.6 N/A 
Female gender, n (%) 26 (86.7) 30 (100) 
Organ/system involved 
Malar rash, n (%) 18 (60.0) N/A 
Photosensitivity, n (%) 17 (56.7) N/A 
Hematological, n (%) 23 (76.6) N/A 
Renal, n (%) 13 (43.4) N/A 
Current antibodies 
ANA positive, n (%) 30 (100) N/A 
Anti-Sm positive, n (%) 5 (16.6) N/A 
Anti-phospholipid (APL) positive, n (%) 6 (20.0) N/A 
Anti-M3 synthetic peptide IgG, n (%) 13 (43.3) 3 (10.0) 
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peptide antibodies were then eluted with 3 M potassium thiocyanate (KSCN) and 1 M sodium chloride (NaCl), 
followed by immediate extensive dialysis against PBS. The IgG concentrations of non-anti-peptide antibodies 
and specific anti-muscarinic receptor peptide IgG were determined by a radial immunodiffusion assay, and their 
immunological reactivity against muscarinic receptor peptides was evaluated by ELISA. The concentration of 
the affinity-purified anti-M3 peptide IgG (1 × 10–7 M) that maximally increased optical density (OD: 2.4 ± 0.2) 
corresponded to a total IgG concentration of 1 × 10–6 M (OD: 2.2 ± 0.2). The normal IgG fraction purified by af-
finity column chromatography gave a negative result (OD: 0.24 ± 0.03).  
3.4. ELISA Assay 
Fifty microlitres of M3 mAChR peptide solution in 0.1 M sodium carbonate (Na2CO3) buffer (pH = 9.6) was 
used to coat microtiter plates (Corning Costar, Tewksbury, MA, USA) at 4˚C overnight as decribed [25]. After 
blocking the wells, varying concentrations of purified IgG from patients with SLE and healthy individuals were 
allowed to react with the antigens for 2 h at 37˚C. The wells were then thoroughly washed with Tween® 20 in 
PBS. Goat anti-human IgG avidin-alkaline phosphatase (50 μl) was added and incubated for 1 h at 37˚C. After 
several washing steps, p-nitrophenyl phosphate (1 mg∙mL−1) was added as the substrate; the reaction was termi-
nated at 30 min. OD values were measured using an ELISA reader (Uniskan Laboratory System, Helsinki, Fin-
land). As negative controls, non-antigen paired wells and wells with no primary antiserum were also tested. 
3.5. PGE2 Procedure 
Serum PGE2 was measured by ELISA according to the manufacturer’s protocol (PGE2 Biotrack Enzyme Im-
mune Assay System; Amersham Bioscience, Piscataway, NJ, USA). The OD cutoff value for PGE2 was 4.4 ± 
0.33 ng/ml. All serum samples were frozen promptly after collection and kept at −80˚C until used for PGE2 de-
termination. The PGE2 results are expressed as ng/mL. 
3.6. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad, San Diego, CA, USA). Statistical signi-
ficance was determined by the two-tailed t test for independent populations. Analysis of variance (ANOVA) and 
Dunn’s and Kruskal-Wallis tests were employed for multiple comparisons. Pearson’s analysis was applied to 
establish correlation. Differences between means were considered significant at P ≤ 0.05. 
3.7. Ethical Approval of the Study Protocol 
The study was approved by the Ethics Committee of the School of Dentistry at Buenos Aires University (Bu-
enos Aires, Argentina). The studies were conducted according to the tenets of the Declaration of Helsinki. All 
participants provided written informed consent to participate in the study. 
4. Results 
ELISA assays were performed to determine whether a correlation exists between serum IgG against M3 mAChR 
synthetic peptide (Figure 1(a)) as well as serum PGE2 levels (Figure 1(b)) in SLE patients compared with nor-
mal individuals. Figure 1(a) shows the optical density (OD) values for each studied serum from SLE patients 
and normal subjects. Also, Figure 1(b) shows serum PGE2 levels in SLE patients and normal subjects. The 
cut-off values obtained with SLE patient sera were always greater than two standard deviations (SD) from those 
from normal individuals. In Figure 1(c), a positive correlation is shown between serum PGE2 levels and anti-M3 
synthetic peptide titers (see table insert) of the individual sera from SLE patients.  
Additionally, Table 2 shows the comparison and a statistical analysis of different autoantibodies from sera of 
SLE patients, showing that anti-M3 synthetic peptide IgG was significantly different from anti-Sm antibodies 
and APL antibodies. No significant values were obtained when we compared anti-M3 synthetic peptide IgG with 
ANA. 
The possible association between SLE disease activity, according to the SLEDAI and levels of anti-M3 syn-
thetic peptide IgG and serum PGE2 levels (expressed as optical density values or ng/ml, respectively) was tested. 
Accordingly, when SLE patients were grouped on the basis of the disease status (active or non-active), no sig-  
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Figure 1. Scattergram showing immunoreactivity of circulating IgG antibodies against M3 
mAChR synthetic peptide (a) and serum PGE2 (b). The individual optical density (OD) values 
for each serum sample (1:30 dilution) from 30 SLE patients and 30 normal individuals. Dot-
ted/dashed line: cutoff values of OD 0.24 and 4.40 for anti-M3 mAChR synthetic peptide IgG 
and serum PGE2, respectively. Solid lines, median OD values. P < 0.0001 between groups, and 
(c) correlation between the anti-M3 synthetic peptide IgG and serum PGE2 levels.                         
 
nificant differences were found for the anti-M3 synthetic peptide IgG (Figure 2(a)). On the contrary, a signifi-
cant association between active or non-active status of SLE patients was observed when we analyzed serum 
PGE2 levels (Figure 2(b)). 
Finally, when we examined the possible association among the three parameters tested (SLEDAI, anti-M3 
synthetic peptide IgG levels, and serum PGE2 levels) in this study, a highly significant association was found  
S. Reina et al. 
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Table 2. Comparison between anti-M3 synthetic peptide IgG and different antibodies in SLE patients.                                
Variable Dunn’s multiple comparison test Number of patients 
Anti-M3 synthetic peptide IgG versus ANA ns 30 
Anti-M3 synthetic peptide IgG versus anti-Sm Yes (P < 0.05) 30 
Anti-M3 synthetic peptide IgG versus APL Yes (P < 0.05) 30 
Results were analyzed by one-way ANOVA followed by Kruskal-Wallis tests (P < 0.0001). 
 
 
 
Figure 2. Scattergram showing immunoreactivity of circulating IgG antibodies against M3 mAChR synthetic peptide (a) and 
serum PGE2 (b) in active and non-active forms of SLE disease. Values are the individual OD values for each serum sample 
from 30 SLE patients and 30 healthy volunteers. Dotted/dashed line: cutoff values of OD 0.24 and 4.40 for anti-M3 mAChR 
synthetic peptide IgG and serum PGE2, respectively. Solid lines, median OD values. P < 0.0001 between groups.                   
 
only between the levels of PGE2 and the active and non-active SLE disease status (SLEDAI) (Table 3). 
5. Discussion 
Systemic lupus erythematosus (SLE) is a challenging disease to assess and manage. Much progress in our un-  
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Table 3. Association between disease activity (SLEDAI) and levels of autoantibodies and serum PGE2.                             
Conditions Active SLE Non-active SLE P values 
SLEDAI 6.51 ± 0.90 0.53 ± 0.23 <0.0001 
Anti-M3 synthetic peptide IgG (optical density 405 nm) 0.73 ± 0.10 0.88 ± 0.22 0.0876 
PGE2 (ng/mL) 54.60 ± 1.39 34.07 ± 2.89 <0.0001 
Number of patients 15 15 N/A 
Values represent the mean ± SEM of 30 patients grouped according to disease activity. 
 
derstanding of its etiopathogenesis has been made. Moreover, differences in the clinical interpretation of the 
signs and symptoms are attributable to the complexity of the disorder and the likely diverse mechanisms that 
contribute to its clinical expression. This extra challenge complicates the work of scientists who seek to under-
stand the disease more fully and clinicians treating patients with SLE. 
SLE is an autoimmune disease that not only can have very different manifestations, but may also share some 
pathogenic mechanisms that may help to identify therapeutic targets.  
In this study, we have shown the differential expression of some autoantibodies, such as ANA, anti-Sm, and 
APL [18] [19], is present at a much higher percentage in sera from SLE patients than in sera from healthy indi-
viduals. In addition, we detected for the first time the presence of anti-M3 synthetic peptide IgG in the serum of 
SLE patients. This autoantibody was significantly associated with anti-Sm and APL antibodies but was unasso-
ciated with ANA. In previous studies was reported that ANA has the highest sensitivity in patients with SLE 
[32]. Moreover, the anti-M3 synthetic peptide IgG was unassociated with malar rash, photosensitivity, or hema-
tologic and renal alterations. 
All of these autoantibodies are also associated with the clinical characteristics in the development of different 
clinical forms of SLE detected both in initial and chronic disease. 
SLE is characterized not only by a dysregulatory immune response including overactive B-cells but is also 
always accompanied by an inflammatory process with T cell hyperactivity, where PGE2 is increased in the se-
rum of SLE patients. That, in turn, not only modulates the immune processes at the sites of inflammation but al-
so has the ability to generate other inflammatory cytokines [28]. However, the increased serum levels of PGE2 in 
SLE patients reveal that this prostanoid mediates the inflammatory process observed in this disease; under iden-
tical experimental conditions, a significant correlation between PGE2 levels and anti-M3 synthetic peptide IgG 
was found. 
These results appear to be a pivotal factor mediated at the level of inflammatory site, maintaining and in-
creasing the production of other proinflammatory cytokines, such as IL-6, IL-10, and nitric oxide [33]. There-
fore, PGE2 and the anti-M3 synthetic peptide antibody could be jointly responsible for the dysregulated produc-
tion of proinflammatory cytokines that maintains the immune-inflammatory process characteristic of this dis-
ease.  
In previous works patients with active discoid SLE were shown to have a strong expression of COX-2 in the 
inflammatory areas [27].  
When SLE patients were grouped on the basis of disease activity (active and non-active disease), no signifi-
cant differences were found for anti-M3 synthetic peptide IgG titers, though a significant difference in serum 
PGE2 levels was observed. Perhaps the increase in PGE2 is necessary to maintain the active inflammatory pro- 
cess in the course of SLE disease. 
Although a possible association exists between the presence of elevated levels of anti-M3 synthetic peptide 
IgG and many different clinical and laboratory parameters, we failed to find a significant correlation with most 
of these parameters. However, a significant correlation between the titer of this cholinergic autoantibody and the 
production of PGE2 was detected. These data suggest that, first, the anti-M3 synthetic peptide IgG may partici-
pate in the onset of the disease, and second, these autoantibodies may contribute to the generation of other 
proinflammatory cytokines. 
6. Conclusion 
On the basis of our results, we have demonstrated significantly enhanced titers of anti-M3 synthetic peptide IgG 
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in patients with SLE, as well as significantly higher levels of serum PGE2. We consider that PGE2 and these 
cholinergic autoantibodies may contribute, in part, to the pathogenesis of the autoreactive and inflammatory 
phenomenon described here and observed in SLE patients. 
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